View Clinical Trial (Medical Research Study)

A Study of the Safety and Tolerability of MEDI-570 (Experimental Drug) in Systemic Lupus Erythematosus - NCT01127321-35294(Clinical Trial 635220)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Birmingham
State:  
AL
Zip Code: 35294
Conditions: Systemic Lupus Erythematosus
Purpose: The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).
Study summary: To evaluate the safety and tolerability of escalating, single, subcutaneous (SC) doses of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).
Criteria: Inclusion Criteria: - Meet or have met at least 4 of the 11 revised American College of Rheumatology (ACR) classification criteria for SLE - Score ≥ 6 points on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at screening - Ability to complete the study period, including follow-up period through Day 169 - Willingness to forego other forms of experimental treatment during the study. Exclusion Criteria: - History of cancer except basal cell carcinoma treated with apparent success with curative therapy ≥ 1 year before randomization into the study - Evidence of active or latent tuberculosis (TB) - History of primary immunodeficiency - Evidence of infection at any time with hepatitis B or C virus or human immunodeficiency virus HIV-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at screening - History of sepsis or serious, recurrent, chronic infection, current signs and symptoms of clinically significant chronic infection, or recent (within 6 months before baseline visit) serious infection - Any history or evidence of opportunistic infection within 6 months of screening including severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes) - Receipt of cyclophosphamide (IV or oral) within 6 months of screening - Have any absolute contraindications to skin punch biopsies, for example, a history of coagulation disorders
Study is available at: Research Site
Birmingham, AL 35294
United States

Primary Contact:
Gerard Barron
Email: barrong@medimmune.com
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.